(18 days)
Not Found
No
The document describes a mass spectrometer system for analyzing stable isotopes in gas samples. It mentions system control, data analysis, and data storage via a personal computer, but there is no mention of AI or ML algorithms being used for these functions or any other part of the device's operation.
No
The device is a mass spectrometer system used for measuring stable isotopes in gas samples, not for treating or diagnosing medical conditions.
No
This device is described as a Gas Isotope Ratio Mass Spectrometer (GIRMS) System intended for measuring stable isotopes in gas samples. While it performs analyses, there's no information provided that directly connects its measurements to diagnosing a medical condition in a patient. Instead, it seems to be an analytical instrument used in research or laboratory settings (e.g., related to a C-urea breath test).
No
The device description explicitly lists multiple hardware components (Gas Isotope Ratio Mass Spectrometer, gas sampling module, gas purification module, autosampler, personal computer) that are integral to the system's function. While a personal computer is mentioned for control and data, the device is not solely software.
Based on the provided text, this device is likely an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is the "measurement of stable isotopes of carbon, nitrogen, and oxygen in gas samples." While not explicitly stating human samples, the performance study mentions "102 breath samples from the "C-urea breath test." The C-urea breath test is a common diagnostic test used to detect Helicobacter pylori infection in humans. This strongly suggests the gas samples being analyzed are derived from human biological specimens.
- Performance Studies: The performance studies directly reference analyzing "breath samples from the "C-urea breath test." This is a clear indication of the device being used for diagnostic purposes on human samples.
- Predicate Device: The predicate device is listed as "ABCA-NT Gas Isotope Ratio Mass Spectrometer System." While the K number isn't immediately searchable without access to the FDA database, the name and the context suggest it's a similar device used for the same purpose, likely also an IVD.
While the "Intended Use / Indications for Use" section is somewhat general, the inclusion of performance data on human breath samples from a diagnostic test makes it highly probable that this device is intended for in vitro diagnostic use.
N/A
Intended Use / Indications for Use
The ABCA is a continuous flow Gas Isotope Ratio Mass Spectrometer (GIRMS) System intended for use in the measurement of stable isotopes of carbon, nitrogen, and oxygen in gas samples. For this purpose, the system is comprised of a gas sampling module, a gas purification module, and an isotope ratio mass spectrometer which are synchronously coupled by means of an external personal computer which also collects and archives data.
Product codes
91DOP
Device Description
The ABCA is an acronym for a configuration of modules intended for use in analysis C and O in CO and N in N and NO gas samples. The ABCA System includes:
- The Europa 20-20 continuous flow IRMS
- A gas purification module (Gas Chromatograph)
- An autosampler
- An IBM (or compatible) personal computer for system control, data analysis and data storage
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Using calculations recommended in NCCLS EP9-A, the mean systematic difference between the predicate device and the modified device at 2.4 Delta Over Baseline (DOB) on 102 breath samples from the "C-urea breath test was determined to be 0.06 DOB.
Using calculations recommended in NCCLS EPS-A, within-run precision at a level of -22% was determined to be 0.056% based on triplicate analyses of stable gas samples in each of 10 daily sample runs. The claimed imprecision at this level is 0.1%.
The ABCA test system response function was determined to be linear throughout the range -22%o to 232%o.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.2860 Mass spectrometer for clinical use.
(a)
Identification. A mass spectrometer for clinical use is a device intended to identify inorganic or organic compounds (e.g., lead, mercury, and drugs) in human specimens by ionizing the compound under investigation and separating the resulting ions by means of an electrical and magnetic field according to their mass.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
KQ Gi 2163
Attachment 4
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is:
Type of Submission: Special 510(k): Device Modification A.
Applicant's Name, Address, Contact Person and Date of Preparation B.
PDZ Europa Limited Europa House, Electra Way Crewe, Cheshire CW1 6ZA United Kingdom
Note that the predicate device 510(k), K974322, was submitted under the name Europa Scientific Limited. Effective November 3, 1998, Europa Scientific Limited (Europa House, Electra Way, Crewe, Cheshire, UK) became PDZ Europa Limited at the same address. PDZ Europa Limited has assumed manufacturing operations and distribution rights for all Europa Scientific's products and services. The Device Establishment Registration Number, Owner/Operator number and Device Listing information has been transferred from Europa Scientific Limited to PDZ-Europa Limited.
Please direct any requests for information to:
Clive Workman Chief Executive PDZ Europa Limited Europa House, Electra Way Crewe, Cheshire CW1 6ZA United Kingdom
Phone: +44-1270-589398 Fax: +44-1270-589412
This 510(k) was prepared June 12, 1999
- Trade Name of the Device: ABCA Gas Isotope Ratio Mass Spectrometer System C.
- D. Common Name of the Device: Gas Isotope Ratio Mass Spectrometer System
E. Classification
| Product Code: | 91DOP |
|---|---|
| Name, Class: | Mass Spectrometer, Clinical Use, Class 1 |
| Reg. Number: | 21CFR 862.2860 |
1
F. The Predicate Device
Trade Name: ABCA-NT Gas Isotope Ratio Mass Spectrometer System 510(k) number: K974322 510(k) clearance date: December 16, 1997
G. Description of the Device
The ABCA is an acronym for a configuration of modules intended for use in analysis ${}^{13}$C and ${}^{18}$O in CO${}_2$ and ${}^{15}$N in N${}_2$ and N${}_2$O gas samples. The ABCA System includes:
- The Europa 20-20 continuous flow IRMS �
- A gas purification module (Gas Chromatograph) �
- � An autosampler
- An IBM (or compatible) personal computer for system control, data analysis and data � storage
1. Principle of Operation
Gas samples for analysis are contained in tubes which may be either pre-evacuated or flushed with air or helium. Most commonly, pre-evacuated tubes such as Exetainers® or Vacutainers® are used and are placed in the holding rack of the autosampler of the System. During operation, the sample probe moves over each tube in turn and either aspirates an aliquot of sample or sweeps the entire gas sample tube to the gas purification module with purified helium. Prior to injection, the probe is purged with helium to rid it of any air.
The helium carrier gas plus sample gases pass through a solid desiccant to remove water vapor, then into a gas chromatographic (GC) column which separates sample gas components. When carbon dioxide is the species of interest. it is undesirable for nitrogen and oxygen to enter the Isotope Ratio Mass Spectrometer. To prevent this, a secondary helium flow moves into the IRMS module while oxygen and nitrogen are directed to waste by a Diverter Valve. As the CO2 emerges from the column, the valves switch to direct the pure CO2 into the IRMS with the secondary helium flow directed to waste.
Once in the IRMS, the neutral molecules, e.g., ${}^{12}$CO${}_2$ and ${}^{13}$CO${}_2$, are ionized in the ‘Source’
producing positively charged ions, e.g., ${}^{13}$CO${}_2$${}^+$ and ${}^{12}$CO${}_2$${}^+$. The charged molecules are then given a precise amount of energy by an electric field and directed into a magnetic field where they follow curved paths dependent on the mass to charge ratio. The separated 'beams' of molecules are focused on three different Faraday 'bucket' collectors, thus generating independent electrical currents corresponding to masses 44, 45, and 46 amu. The ratio of currents generated at the 45 and 44 amu collectors corresponds to the ratio of ${}^{13}$CO${}_2$ to ${}^{12}$CO${}_2$ in the original gas sample. The current generated at the 46 amu collector corresponds to the ${}^{12}$C${}^{16}$O${}^{18}$O${}^+$ ion and is used to correct for contributions of ${}^{12}$C${}^{16}$O${}^{17}$O${}^+$ to the 45 amu current using the Craig correction since the ${}^{17}$O/${}^{18}$O ratio is constant.
2
2. Calibration
The system is calibrated with reference gas of known isotopic composition. The reference gas may be contained in sample tubes in the autosampler or may be introduced directly from a gas cylinder.
Calculation of Results 3.
For a given gas specimen, the ratio of the electrical current signals from the ${}^{13}CO_2^+$ and ${}^{12}CO_2^+$ ions is compared to that obtained when a reference CO2 sample of known isotopic abundance is introduced into the GIRMS system under identical conditions. The result of this differential measurement is expressed as the "delta per mil" difference between the (${}^{13}CO_2/{}^{12}CO_2$) ratio of the sample (RB) and the reference (RS):
$$\text{So } ^{13}\text{C} = \frac{R_B - R_S}{R_S} \text{ * 1000, *\text{@}}$$
The symbol for the "delta per mil" unit is %0.
Intended Use E.
The ABCA is a continuous flow Gas Isotope Ratio Mass Spectrometer (GIRMS) System intended for use in the measurement of stable isotopes of carbon, nitrogen, and oxygen in gas samples. For this purpose, the system is comprised of a gas sampling module, a gas purification module, and an isotope ratio mass spectrometer which are synchronously coupled by means of an external personal computer which also collects and archives data.
F. Summary of Modifications to the Predicate Device
Hardware Modifications
- a) The gas purification (gas chromatograph) module, gas sampling module and the sample injector are housed in a single cabinet to reduce counter space requirements.
- b) A redesigned gas sampling module allows sampling an aliquot of gas samples instead of using the entire sample. This permits re-sampling if necessary.
- c) A re-sized gas chromatographic column and reduced helium carrier gas flow allow smaller samples and improved chromatographic resolution.
- d) An option for direct reference gas injection from a reference gas cylinder eliminates the need to occupy patient sample or QC tube positions in the autosampler with reference gas tubes.
3
Software Modifications
- The Microsoft Visual Basic compiler was upgraded from VB 3.0 to VB 5.0. Software a) was revised to compile under VB 5.0.
- b) New program code was introduced for mass spectrometer operation and control of the new gas sampler.
- c) Addition of a macro language enables automation of routine operations, provides easier code maintenance and facilitates research applications.
- d) A modified graphical user interface facilitates data entry and data storage.
G. Substantial Equivalence
The modified ABCA GIRMS System has the following similarities to the ABCA-NT System which previously received 510(k) clearance:
-
- Has the same intended use
- Uses the same fundamental scientific technology 2.
-
- Incorporates the same basic Europa GIRMS design
- Calibrates using the same principle 4.
-
- Calculates final results identically
-
- Has substantially equivalent technical specifications
In summary, the ABCA Gas Isotope Ratio Mass Spectrometer described in this submission is substantially equivalent to the predicate device.
H. Analytical Performance Data
- Using calculations recommended in NCCLS EP9-A, the mean systematic difference 1. between the predicate device and the modified device at 2.4 Delta Over Baseline (DOB) on 102 breath samples from the "C-urea breath test was determined to be 0.06 DOB.
-
- Using calculations recommended in NCCLS EPS-A, within-run precision at a level of -22% was determined to be 0.056% based on triplicate analyses of stable gas samples in each of 10 daily sample runs. The claimed imprecision at this level is 0.1%.
-
- The ABCA test system response function was determined to be linear throughout the range -22%o to 232%o.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with its wings forming three curved lines.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUL 1 3 1999
PDZ Europa Limited c/o Dr. Robert F. Martin MarChem Associates, Inc. 325 College Road Concord, Massachusetts 01742
K992163 Re:
Trade Name: ABCA-NT Gas Isotope Ratio Mass Spectrometer System Regulatory Class: I reserved Product Code: DOP Dated: June 24, 1999 Received: June 25, 1999
Dear Mr. Workman:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrl/dsma/dsmamain.html".
Sincerely yours.
Steven Sutman
Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Attachment 1
Indications for Use Statement
Device Name:
ABCA Gas Isotope Ratio Mass Spectrometer System
Indications for Use:
The ABCA is a continuous flow Gas Isotope Ratio Mass Spectrometer (GIRMS) System intended for use in the measurement of stable isotopes of carbon, nitrogen, and oxygen in gas samples. For this purpose, the system is comprised of a gas sampling module, a gas purification module, and an isotope ratio mass spectrometer which are synchronously coupled by means of an external personal computer which also collects and archives data.
Prescription Use: No
Hencooper
(Division Sign-Off)
ision of Clinical Labo oratory Devices 510(k) Number